Telbivudine: a new option for the treatment of chronic hepatitis B. (Q36810314)

16 August 2017

1 reference

title

Telbivudine: a new option for the treatment of chronic hepatitis B. (English)

1 reference

16 August 2017

1 reference

Julie Sheldon

2

0 references

Vicente Soriano

series ordinal

3

object named as

Vincent Soriano

1 reference

16 August 2017

Andrés Ruiz-Sancho

1

1 reference

PubMed ID

17477811

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

751-761

1 reference

16 August 2017

5

1 reference

Hepatitis B virus infection--natural history and clinical consequences

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Natural history of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Natural history and prognostic factors for chronic hepatitis type B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Asian-Pacific consensus statement on the management of chronic hepatitis B: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Lamivudine treatment in patients with chronic hepatitis B and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Variant of hepatitis B virus with primary resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

21 January 2018

Atazanavir urolithiasis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Mutations affecting the replication capacity of the hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.5.751

21 January 2018

Identifiers

DOI

10.1517/14712598.7.5.751

1 reference

16 August 2017

1 reference

PubMed ID

17477811